Edgewell's Return to Growth: A Pivotal Quarter and a Rejection of an Unwanted Suitor
Return to Growth
In a quarter management dubbed "an important step forward," Edgewell Personal Care finally delivered on the promise of a back-half inflection. “Organic net sales returned to growth, driven by a meaningful improvement in North America, where performance exceeded our expectations.” — Rod Little, President and Chief Executive Officer · 2026-08-05 The market has taken notice — the stock has rallied roughly 30% over the past 90 days, though it remains far off its 2015 peak. The return to growth was broad-based: North America organic sales grew 3%, while international slipped 1.4% on transient private-label supply disruptions.
The Quarter: Brands Are Working
Behind the headline, the portfolio is showing life. “Cremo is now 20-plus percent for the seventh consecutive quarter” — Rod Little, President and Chief Executive Officer · 2026-08-05, and Hawaiian Tropic has climbed to the #4 Sun Care brand, up from #6 a year ago. Billie continues to gain share, and the brand momentum is beginning to translate into marketplace results — branded search activity and household penetration are both trending up. At the same time, tariff refunds provided a modest offset to input-cost inflation, echoing a theme repeated across the consumer sector this earnings season: the tariff refund benefit is showing up in margins for companies with U.S. manufacturing flexibility.
The Transformation Story
The bigger change is structural. manufacturing consolidation in Wet Shave — the largest operational initiative since the company's 2015 spin-off — is nearing its inflection point. Management is also investing in technology and AI-enabled capabilities to drive productivity and lower the cost base. That's the foundation of their confidence in meaningful gross margin expansion in Q4 and into fiscal 2027. Gross margin is expected to expand, with productivity savings reaching full run rate. CFO Fran Weissman reaffirmed the plan: “We also continue to expect material gross margin expansion in the fourth quarter, driven primarily by significant productivity savings.” — Francesca Weissman, Chief Financial Officer · 2026-08-05
The setup heading into 2027 is what Rod Little calls "a position of strength": better execution, a more focused portfolio post–Fem Care divestiture, improving U.S. performance, and a transformation nearing payback. He did not provide explicit guidance but signaled “we should be growing next year” — Rod Little, President and Chief Executive Officer · 2026-08-05, with low single-digit organic growth as a credible algorithm.
The Elephant in the Room
During the quarter, reports surfaced of an unsolicited acquisition approach that the board rejected as insufficient. Rod Little declined to comment directly but stressed the board's fiduciary duty.
The stock's recent strength suggests the market sees optionality — either in the organic turnaround or in a potential bidder returning at a higher price.We can't comment specifically on rumors or speculation in the market. ... The Board has a fiduciary duty. If there's ever something that comes inbound that can beat that organic plan, which we have financial advisers and legal advisers, we go through a very strict fiduciary process to consider anything that's inbound versus the value of the organic plan.
Prior-quarter calls set the stage: management had consistently framed fiscal 2026 as a "back half story" and promised not to cut brand investment. “We are not cutting brand investment and we're not cutting A&P to do this.” — Rod Little, President and Chief Executive Officer · 2026-05-06 The commitment to productivity and pricing as levers was also telegraphed: “We continue to focus on SRGM as well as mix management. ... Pricing is going to be a lever.” — Francesca Weissman, Chief Financial Officer · 2026-05-06 This quarter's results validate those promises — and the unsolicited offer confirms that the market is beginning to re-rate the story.